Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 234

1.

B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation.

Inohara T, Kim S, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP; ORBIT AF Patients and Investigators.

Heart. 2018 Sep 18. pii: heartjnl-2018-313642. doi: 10.1136/heartjnl-2018-313642. [Epub ahead of print]

PMID:
30228248
2.

Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Jackson LR 2nd, Kim S, Shrader P, Blanco R, Thomas L, Ezekowitz MD, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP Sr.

J Thromb Thrombolysis. 2018 Nov;46(4):435-439. doi: 10.1007/s11239-018-1715-1.

PMID:
30051164
3.

Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.

Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, Oldgren J, Reilly PA, Wallentin L, Ezekowitz MD.

J Am Coll Cardiol. 2018 Jul 17;72(3):255-267. doi: 10.1016/j.jacc.2018.04.063. Epub 2018 Jul 9.

PMID:
30012318
4.

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study.

Goette A, Kwong WJ, Ezekowitz MD, Banach M, Hjortshoj SP, Zamoryakhin D, Lip GYH.

Europace. 2018 Jun 27. doi: 10.1093/europace/euy141. [Epub ahead of print]

PMID:
29947751
5.

Patients With Atrial Fibrillation: Switching Emphasis From Stroke Prevention to Stroke and Hemorrhage Prevention.

Ezekowitz MD, Chandhok S, Arce JE.

JACC Clin Electrophysiol. 2017 Dec 11;3(12):1377-1379. doi: 10.1016/j.jacep.2017.06.021. Epub 2017 Nov 6. No abstract available.

PMID:
29759667
6.

Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients with Atrial Fibrillation.

O'Brien EC, Holmes DN, Thomas LE, Fonarow GC, Allen LA, Gersh BJ, Kowey PR, Singer DE, Ezekowitz MD, Naccarelli GV, Ansell JE, Chan PS, Mahaffey KW, Go AS, Freeman JV, Reiffel JA, Peterson ED, Piccini JP, Hylek EM.

Circulation. 2018 Apr 20. pii: CIRCULATIONAHA.117.031354. doi: 10.1161/CIRCULATIONAHA.117.031354. [Epub ahead of print]

PMID:
29678813
7.

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.

Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P.

Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148.

8.

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis.

Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L.

Am Heart J. 2018 Apr;198:169-177. doi: 10.1016/j.ahj.2017.10.015. Epub 2018 Jan 5. No abstract available.

PMID:
29653640
9.

Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).

Steinberg BA, Shrader P, Pieper K, Thomas L, Allen LA, Ansell J, Chan PS, Ezekowitz MD, Fonarow GC, Freeman JV, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli GV, Reiffel JA, Singer DE, Peterson ED, Piccini JP; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) II Investigators.

J Am Heart Assoc. 2018 Feb 16;7(4). pii: e007633. doi: 10.1161/JAHA.117.007633.

10.

International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.

Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz MD, Fonarow GC, Gersh BJ, Goldhaber S, Haas S, Hacke W, Kowey PR, Ansell J, Mahaffey KW, Naccarelli G, Reiffel JA, Turpie A, Verheugt F, Piccini JP, Kakkar A, Peterson ED, Fox KAA; GARFIELD-AF; ORBIT-AF Investigators.

Am Heart J. 2017 Dec;194:132-140. doi: 10.1016/j.ahj.2017.08.011. Epub 2017 Aug 24.

11.

The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.

Lip GYH, Al-Saady N, Ezekowitz MD, Banach M, Goette A.

Am Heart J. 2017 Nov;193:16-22. doi: 10.1016/j.ahj.2017.07.010. Epub 2017 Jul 20.

PMID:
29129251
12.

Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study.

Inohara T, Shrader P, Pieper K, Blanco RG, Thomas L, Singer DE, Freeman JV, Allen LA, Fonarow GC, Gersh B, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Steinberg BA, Peterson ED, Piccini JP.

JAMA Cardiol. 2018 Jan 1;3(1):54-63. doi: 10.1001/jamacardio.2017.4665.

PMID:
29128866
13.

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.

Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators.

Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.

14.

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.

Proietti M, Hijazi Z, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Lane DA, Oldgren J, Roldan V, Yusuf S, Wallentin L; RE-LY Investigators.

J Intern Med. 2018 Mar;283(3):282-292. doi: 10.1111/joim.12702. Epub 2017 Nov 7.

PMID:
29044861
15.

The impact of IMPACT-AF.

Ezekowitz MD, Kent AP.

Lancet. 2017 Oct 14;390(10104):1717-1718. doi: 10.1016/S0140-6736(17)32248-1. Epub 2017 Aug 28. No abstract available.

PMID:
28859948
16.

Disease understanding in patients newly diagnosed with atrial fibrillation.

Kaufman BG, Kim S, Pieper K, Allen LA, Gersh BJ, Naccarelli GV, Ezekowitz MD, Fonarow GC, Mahaffey KW, Singer DE, Chan PS, Freeman JV, Ansell J, Kowey PR, Rieffel JA, Piccini J, Peterson E, O'Brien EC.

Heart. 2018 Mar;104(6):494-501. doi: 10.1136/heartjnl-2017-311800. Epub 2017 Aug 8.

17.

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Siegbahn A, Wallentin L.

Am Heart J. 2017 Aug;190:94-103. doi: 10.1016/j.ahj.2017.06.001. Epub 2017 Jun 6.

PMID:
28760218
18.

Internal Carotid Artery and Sphenoidal Emissary (Vesalian) Vein Fistula Mimicking a Carotid-Cavernous Sinus Fistula.

Liberman AL, Ramchand P, Gannon K, Zager EL, Pukenas B, Bress AL, Ezekowitz MD, Hurst R, Messé SR.

Neurohospitalist. 2017 Jul;7(3):NP1-NP2. doi: 10.1177/1941874416672803. Epub 2016 Oct 14. No abstract available.

19.

Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.

Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G.

Europace. 2018 Feb 1;20(2):253-262. doi: 10.1093/europace/eux022.

20.

Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.

Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY; ENSURE-AF investigators.

Lancet. 2016 Oct 22;388(10055):1995-2003. doi: 10.1016/S0140-6736(16)31474-X. Epub 2016 Aug 30. Erratum in: Lancet. 2016 Oct 22;388(10055):1984.

PMID:
27590218

Supplemental Content

Loading ...
Support Center